Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years’ follow-up
Following the publication of this article, the authors noted the following sentence could be misinterpreted: 'In patients with ALK-sALCL, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5-70.2%)and 56.0%(39.3-69.7%) in the A + CHP and CHOP arms, respectively'.This sentence is in fact about patients with ALK-sALCL who achieved a complete response (CR), and while the sentence appears in the context of a paragraph discussing patients with a CR, the following correction has been made to avoid confusion: 'In patients with ALK-sALCL who achieved CR, the estimated 5-year PFS rate (95% CI) was 56.8% (40.5-70.2%)and 56.0%(39.3-69.7%) in the A + CHP and CHOP arms, respectively'.Data showing 5-year PFS in patients with ALKdisease, regardless of response, appear in Figure 1.
Authors
- Cassie Dong
- Tatyana A. Feldman (ORCID: https://orcid.org/0000-0002-4458-2896)
- Kerry J. Savage (ORCID: https://orcid.org/0000-0002-5835-9863)
- Deepa Jagadeesh
- P. L. Zinzani
- Jonathan W. Friedberg (ORCID: https://orcid.org/0000-0002-1420-5563)
- Keenan Fenton (ORCID: https://orcid.org/0009-0001-1972-6296)
- G. Gritti
- Andrei R. Shustov
- David Belada (ORCID: https://orcid.org/0000-0002-4981-6188)
- Andreas Hüttmann (ORCID: https://orcid.org/0000-0003-2230-3873)
- Michelle A. Fanale (ORCID: https://orcid.org/0000-0003-3880-0866)
- Ilseung Choi (ORCID: https://orcid.org/0000-0002-8920-7045)
- Meredith Little
- Jacob Haaber Christensen
- Lorenz Trümper
- Eva Domingo-Domenech
- Steven Horwitz
- Marek Trneny
- Ranjana Advani
- Steven Le Gouill
- Nancy L. Bartlett
- Tim Illidge
- Barbara Pro
- Swami Iyer
- Arpad Illes
- Won-Seog Kim
Institutions
- Northwestern University (US)
- Cleveland Clinic (US)
- University of Debrecen (HU)
- Seattle Cancer Care Alliance (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Washington University in St. Louis (US)
- Charles University (CZ)
- Columbia University Irving Medical Center (US)
- Manchester Academic Health Science Centre (GB)
- Odense University Hospital (DK)
- Spinal Cord Injury BC (CA)
- Samsung Medical Center (KR)
- National Hospital Organization Kyushu Cancer Center (JP)
- Ospedale Papa Giovanni XXIII (IT)
- Institut Català d'Oncologia (ES)
- Universitätsmedizin Göttingen (DE)
- Istituto di Ematologia di Bologna (IT)
- Essen University Hospital (DE)
- Stanford Medicine (US)
- University Hospital Hradec Králové (CZ)
- Takeda (United States) (US)
- Cellectar Biosciences (United States) (US)
- Hackensack Meridian Health (US)
- TE Laboratories (Ireland) (IE)
- NIHR Manchester Biomedical Research Centre (GB)
- University of Rochester (US)
- Vertex Pharmaceuticals (United States) (US)
- Institut Curie (FR)
- Sungkyunkwan University (KR)
- University of Bologna (IT)
- Stanford University (US)
- Seagen (United States) (US)
Publication Details
- Journal
- Blood Cancer Journal
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1038/s41408-025-01432-4
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00